caa a22 4500 477056210 CHVBK 20180405111347.0 cr unu---uuuuu 170330e19961201xx s 000 0 eng 10.1007/s002280050197 doi (NATIONALLICENCE)springer-10.1007/s002280050197 Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: lack of interactions [Elektronische Daten] [A. Illi, S. Sundberg, P. Ojala-Karlsson, M. Scheinin, A. Gordin] Objective: We have evaluated the effects of simultaneous inhibition of catechol-O-methyltransferase (COMT) by entacapone and of neuronal monoamine reuptake by imipramine on haemodynamics and catecholamine metabolism, and the safety and tolerability of the drug combination in healthy women. Methods: In a randomized, single-dose, single-blind, cross-over study, 12 healthy women were given placebo, entacapone (200 mg), imipramine (75 mg) or entacapone and imipramine in combination. Heart rate, blood pressure, systolic time intervals, and plasma concentrations of catecholamines and their metabolites were measured at rest and during exercise. Results: The only drug-related effect on haemodynamics was an increase in heart rate during exercise after imipramine. The increase in heart rate after the combination of entacapone and imipramine was similar to that after imipramine alone. Entacapone alone had no effects on haemodynamics. Imipramine and entacapone had no significant effects on the plasma concentrations of noradrenaline and adrenaline. No interactions between entacapone and imipramine were detected. Springer-Verlag Berlin Heidelberg, 1996 Key words Entacapone nationallicence Imipramine nationallicence COMT inhibition nationallicence haemodynamics nationallicence catecholamine metabolism nationallicence systolic time intervals nationallicence Illi A. Orion Research Center, PO Box 65, FIN-02101 Espoo, Finland Tel.: (0) 429-3471; Fax: (0) 429-2924, FI aut Sundberg S. Orion Research Center, PO Box 65, FIN-02101 Espoo, Finland Tel.: (0) 429-3471; Fax: (0) 429-2924, FI aut Ojala-Karlsson P. Department of Pharmacology and Clinical Pharmacology, University of Turku, Turku, Finland, FI aut Scheinin M. Department of Pharmacology and Clinical Pharmacology, University of Turku, Turku, Finland, FI aut Gordin A. Orion Research Center, PO Box 65, FIN-02101 Espoo, Finland Tel.: (0) 429-3471; Fax: (0) 429-2924, FI aut https://doi.org/10.1007/s002280050197 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280050197 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Illi A. Orion Research Center, PO Box 65, FIN-02101 Espoo, Finland Tel.: (0) 429-3471; Fax: (0) 429-2924, FI aut NATIONALLICENCE 700 1- Sundberg S. Orion Research Center, PO Box 65, FIN-02101 Espoo, Finland Tel.: (0) 429-3471; Fax: (0) 429-2924, FI aut NATIONALLICENCE 700 1- Ojala-Karlsson P. Department of Pharmacology and Clinical Pharmacology, University of Turku, Turku, Finland, FI aut NATIONALLICENCE 700 1- Scheinin M. Department of Pharmacology and Clinical Pharmacology, University of Turku, Turku, Finland, FI aut NATIONALLICENCE 700 1- Gordin A. Orion Research Center, PO Box 65, FIN-02101 Espoo, Finland Tel.: (0) 429-3471; Fax: (0) 429-2924, FI aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer